
Loading, please wait...

Loading, please wait...

The Delhi High Court recently heard a case of a three-year-old child diagnosed with LRBA deficiency. Consequently, this case highlights the strict criteria for rare disease financial assistance under the NPRD 2021. Specifically, the Union Government opposes the child's plea because her condition does not appear on the notified list. Therefore, she currently lacks access to lifesaving financial support.
LRBA deficiency represents a rare genetic immune disorder that severely impairs immune system regulation. As a result, patients experience recurrent life-threatening infections and severe multi-system autoimmune complications. Specialists at AIIMS Delhi and CMC Vellore confirmed this diagnosis using whole-genome sequencing. Ultimately, clinical experts concluded that an allogeneic hematopoietic stem cell transplant is the only curative option. However, this complex procedure costs approximately Rs 40 lakh, placing an immense burden on the family.
For instance, the NPRD 2021 framework provides substantial financial support up to Rs 50 lakh per patient. However, the policy limits this assistance to only 63 notified rare diseases. Furthermore, since the policy omits LRBA deficiency from this list, the government rejected the petitioner's funding request. Additionally, the Centre maintained that expanding the disease list is strictly a policy decision. Thus, judicial intervention cannot mandate changes to the current executive policy framework. In addition, the government noted that public health remains primarily under State Government jurisdiction.
Q1: What is LRBA deficiency?
LRBA deficiency is a rare and severe genetic immune disorder caused by mutations in the LRBA gene. It severely impairs immune regulation, leading to frequent infections, anemia, and autoimmune complications across multiple organs.
Q2: Why did the government deny funding under the NPRD 2021?
The Union Government denied assistance because LRBA deficiency is not currently among the 63 notified rare diseases covered under the National Policy for Rare Diseases (NPRD), 2021 framework.
Q3: What is the maximum financial aid available under NPRD 2021?
The National Policy for Rare Diseases provides financial support of up to Rs 50 lakh per eligible patient, with diagnostic and treatment requests routed through 15 designated Centres of Excellence.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A three-year-old child's petition for LRBA deficiency treatment highlights the strict limits of India's NPRD 2021. Since the genetic condition is not listed among the 63 notified diseases, the Centre has declined funding, arguing that policy expansion is an executive rather than a judicial decision.
2 months ago

As India's geriatric demographic prepares to double to 346 million by 2050, national health initiatives are expanding. From universal PM-JAY insurance for individuals aged 70 and above to institutional care homes and dedicated digital caregiver dashboards, proactive public healthcare models are reshaping eldercare.
Yesterday

The Maharashtra public health department has established a specialized task force headed by Dr. Neelam Gorhe to eliminate illegal sex determination and unauthorized abortions. The team will execute surprise inspections of ultrasound facilities, audit medical documentation, and enforce strict statutory standards.
Yesterday

A major cybersecurity breach disrupted global operations at Boston Scientific, delaying device distribution and remote cardiac monitoring activations. This analysis examines the immediate consequences for clinical catheterization suites, electrophysiology teams, hospital inventory systems, and patient care safety.
Yesterday

Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
2 months ago

A nationwide mixed-methods study evaluated hospital glycemic management systems across 265 hospitals. While real-time alerts and automatic data sync are highly valued, significant disparities in digital maturity and low satisfaction with decision support highlight the need for standardized implementation.
Last week